Product sales

Product sales

Full year 2025 product sales

The following table provides the top 20 product net sales from continuing operations in 2025, as well as the change compared with 2024:

Brands
 		Net Sales
(USD m)		% change
(USD)		% change
(cc1)		Brand classification by therapeutic area or established brands
Entresto7,748-1-2Cardiovascular, renal and metabolic
Cosentyx6,66898Immunology
Kisqali4,7835857Oncology
Kesimpta4,4263736Neuroscience
Tafinlar + Mekinist2,21586Oncology
Jakavi2,11097Oncology
Pluvicto1,9944342Oncology
Ilaris1,8832524Immunology
Xolair21,72354Immunology
Promacta/Revolade1,636-26-27Oncology
Scemblix1,2858785Oncology
Zolgensma Group1,23210Neuroscience
Sandostatin Group1,213-5-5Established brands
Leqvio1,1985957Cardiovascular, renal and metabolic
Tasigna1,104-34-34Oncology
Lutathera8161312Oncology
Exforge Group72734Established brands
Lucentis643-38-40Established brands
Diovan Group60422Established brands
Fabhalta3505291287Oncology
  1. For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2025: “—Non-IFRS measures as defined by Novartis.”
  2. Net sales from continuing operations reflect Xolair sales for all indications.
  3. Net sales from continuing operations reflect Fabhalta sales for all indications.
Source URL: https://www.novartis.com/investors/financial-data/product-sales

List of links present in page
  1. https://www.novartis.com/investors/financial-data/product-sales